Breast Cancer Res Treat (2016) 159: 481.

Raquel A. Nunes, Lynette Wray, Mihriye Mete, Pia Herbolsheimer, Karen L. Smith, Lana Bijelic, Marc E. Boisvert, Sandra M. Swain

We evaluated gene expression in tumors from AAF presenting with early stage or locally advanced breast cancer using MammaPrint, BluePrint (molecular subtype) and TargetPrint, correlated with OncotypeDX and clin-path. High Risk MammaPrint was present in 66% of patients and in 52% of patients with stage I disease.

Read more: Nunes et al_2016_Breast Cancer Research and Treatment_Genomic profiling of breast cancer in African-American women using MammaPrint